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Elevated cardiovascular risk among adults with
obstructive and restrictive airway functioning in
the United States: a cross-sectional study of the
National Health and Nutrition Examination Survey
from 2007–2010
Earl S Ford1,4*, Anne G Wheaton1, David M Mannino2, Letitia Presley-Cantrell1, Chaoyang Li3 and Janet B Croft1
Abstract
Background: Reasons for the excess risk for cardiovascular disease among people with chronic obstructive
pulmonary disease remain unclear. Our objective was to examine the cardiovascular risk profile for adults with
obstructive and restrictive impairments of lung functioning in a representative sample of adults from the
United States.
Methods: We used data from adults aged 20–79 years who participated in the National Health and Nutrition
Examination Survey from 2007 to 2010 and had a pulmonary function test. The severity of obstructive
impairment was defined by adapting the Global Initiative for Chronic Obstructive Lung Disease criteria.
Results: Among 7249 participants, 80.9% had a normal pulmonary function test, 5.7% had a restrictive impairment,
7.9% had mild obstructive impairment, and 5.5% had moderate or severe/very severe obstructive impairment.
Participants with obstructive impairment had high rates of smoking and increased serum concentrations of
cotinine. Compared to participants with normal pulmonary functioning, participants with at least moderate
obstructive impairment had elevated concentrations of C-reactive protein but lower concentrations of total
cholesterol and non-high-density lipoprotein cholesterol. Among participants aged 50–74 years, participants with at
least a moderate obstructive impairment or a restrictive impairment had an elevated predicted 10-year risk for
cardiovascular disease.
Conclusions: The high rates of smoking among adults with impaired pulmonary functioning, particularly those
with obstructive impairment, point to a need for aggressive efforts to promote smoking cessation in these adults. In
addition, adults with restrictive impairment may require increased attention to and fine-tuning of their
cardiovascular risk profile.
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Background
Over 137,000 deaths were preliminarily ascribed to
chronic lower respiratory diseases in 2010 resulting in
this group of lung disorders continuing to be ranked for
the third straight year as the third leading cause of death
in the United States [1]. Over 95% of these respiratory
deaths are attributed to chronic obstructive pulmonary
disease (COPD), which includes emphysema and chronic
bronchitis. People with COPD have a higher mortality
rate than those who do not have COPD [2]. Further-
more, people with COPD are at increased risk of devel-
oping or dying from cardiovascular disease [2-10]. Also,
impaired lung function as measured by the forced ex-
piratory volume in one second (FEV1) flow is inversely
associated with cardiovascular events [11,12]. These
observations raise questions about the cardiovascular
risk profile among people with COPD. Among deaths
from bronchitis, emphysema, and chronic airway ob-
struction in the United States in 2000–2004, 82.2% were
attributed to cigarette smoking [13]. Because smoking is
considered the major cause of COPD in many societies,
the high prevalence of smoking among people with
COPD likely accounts for part or perhaps most of the
increased risk. However, the possible contribution to
increased mortality from cardiovascular disease by other
risk factors is less well understood. Clarification of the
possible cardiovascular factors that may increase the risk
for cardiovascular disease mortality would help in direct-
ing the clinical management of adults with COPD in
order to mitigate this extra risk. Therefore, the primary
objective of the present study was to compare cardiovas-
cular risk factors between adults with and without
COPD determined from spirometry. In addition, we also
examined the cardiovascular risk profile among adults
with a restrictive impairment.
Methods
Participants of the National Health and Nutrition Exam-
ination Survey (NHANES) 2007–2010 were selected by
using a stratified multistage probability sample. After
agreeing to participate, invitees were interviewed in their
homes and asked to attend an examination in the mobile
examination center. Attendees completed additional
questionnaires, underwent various examinations, and
were phlebotomized. Response rates for the interview
and examination were 78% and 75%, respectively, in
NHANES 2007–2008, and 79% and 77%, respectively, in
NHANES 2009–2010. The NHANES website offers
detailed information about the surveys [14]. NHANES
2007–2010 was approved by the National Center for
Health Statistics (NCHS) Research Ethics Review Board.
Spirometry was offered to participants aged 6–79 years
in NHANES 2007–2010 [15,16]. Participants were
excluded for the following reasons: current chest pain;
physical problem with forceful expiration; use of supple-
mental oxygen; recent surgery of the eye, chest or the
abdomen; recent heart attack, stroke, tuberculosis expos-
ure, or coughing up of blood; and history of detached
retina or a collapsed lung. Participants were asked to
provide three acceptable maneuvers using Ohio 822/827
dry-rolling seal volume spirometers [16].
We used predictive equations for forced expiratory
volume in 1 second (FEV1) and forced vital capacity
(FVC) that were derived from NHANES III data [17].
We applied the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) classification, which was designed
for use with postbronchodilator results, to the pre-
bronchodilator spirometric results and established the
following categories of obstructive impairment: severe
obstructive impairment (FEV1/ FVC <0.70 and FEV1
<50% predicted), moderate obstructive impairment
(FEV1/FVC <0.70 and FEV1 50 to <80% predicted), and
mild obstructive impairment (FEV1/FVC <0.70 and
FEV1 ≥80% predicted). Because the number of partici-
pants with severe obstructive impairment was limited,
we combined participants with moderate and severe ob-
structive impairment into one group. Participants with a
FEV1/FVC ratio ≥0.70 were considered as not having
obstructive impairment [18]. In addition, we also defined
a category of restrictive impairment (FEV1/FVC ≥0.70
and FVC <80% predicted) for some analyses.
Participants who had an obstructive impairment as
defined by FEV1/FVC less than 70% or the lower limit
of normal were eligible for bronchodilator testing. Exclu-
sion criteria included the following: cardiovascular con-
ditions (uncontrolled blood pressure, irregular pulse on
examination, taking medication for major arrhythmia,
implanted defibrillator, or history of congenital heart dis-
ease), taking certain prescription medications (mon-
amine oxidase inhibitors, anticonvulsants, tricyclic
antidepressants, current treatment for cardiac disease,
potassium lowering drugs), recent use of β2-adrenergic
bronchodilators, previous adverse reaction to albuterol,
pregnancy, and breastfeeding. In all, almost half of adults
did not complete this portion of the protocol because of
exclusion criteria or other reasons. We classified the
postbronchodilator results as above to create groups
with mild, moderate, and severe or very severe obstruct-
ive impairment and retained the groups with normal
lung function and restrictive impairment based on the
prebronchodilator results.
We examined the following cardiovascular risk factors:
smoking status, concentration of cotinine, hypertension,
hypercholesterolemia, low concentration of high-density
lipoprotein cholesterol (<1.03 mmol/L in men and
<1.29 mmol/L in women), non-high-density lipoprotein
cholesterol ≥3.36 mmol/L, low-density lipoprotein chol-
esterol ≥2.59 mmol/L, C-reactive protein >3 mg/dl,
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diagnosed diabetes, body mass index ≥30 kg/m2, abdom-
inal obesity (≥102 cm in men, ≥88 cm in women),
leisure-time physical activity <150 minutes per week. A
current smoker was defined as someone who had
smoked at least 100 cigarettes during his or her lifetime
and reported still currently smoking. A former smoker
was defined as someone who had smoked at least 100
cigarettes during his or her lifetime but reported having
stopped smoking. A never smoker was defined as some-
one who had not smoked at least 100 cigarettes during
his or her lifetime. Up to four attempts were made to
measure blood pressure. The average of the last two
measurements of blood pressure for participants who
had three measurements, the last measurement for
participants with only two measurements, and the only
measurement for participants who had one measure-
ment were used. Hypertension was defined as a sys-
tolic blood pressure ≥140 mm Hg or a diastolic blood
pressure ≥90 mm Hg or the self-reported use of anti-
hypertensive medications. Body mass index (kg/m2)
was calculated from measured weight and height.
Waist circumference at the level of the ilium was mea-
sured to nearest 1 mm at the end of normal expir-
ation. If participants responded affirmatively to the
question “Have you ever been told by a doctor or
health professional that you have diabetes or sugar dia-
betes?”, they were considered to have diagnosed dia-
betes. Participants who reported having borderline
diabetes were considered as not having diagnosed
diabetes.
Serum concentrations of cotinine were measured with
isotope-dilution high-performance liquid chromatog-
raphy /atmospheric pressure chemical ionization tandem
mass spectrometric method. Concentrations of total
cholesterol were measured with an enzymatic method
on a Roche Modular P chemistry analyzer (Roche Diag-
nostics, Indianapolis, IN) during 2007–2008 and on a
Beckman Coulter UniCel DxC800 Synchron Clinical
System (Beckman Coulter, Inc., Brea, CA) during 2009–
2010. Concentrations of high-density lipoprotein
cholesterol were measured after precipitation with
magnesium/dextran sulfate on a Roche Modular P
chemistry analyzer (Roche Diagnostics, Indianapolis,
IN). Concentrations of non-high-density lipoprotein
cholesterol were calculated by subtracting concentra-
tions of high-density lipoprotein cholesterol from those
of total cholesterol. Concentrations of low-density lipo-
protein cholesterol were calculated by using the Friede-
wald equation only for fasting participants who had
fasted from 8.5 to 24 hours and attended the morning
examination. Concentrations of C-reactive protein were
measured by latex-enhanced; nephelometry on a Dade
Behring Nephelometer II Analyzer System (BNII) (Dade
Behring Diagnostics Inc., Somerville, NJ).
We used a multivariable risk algorithm derived from
Framingham data to calculate the predicted 10-year car-
diovascular risk for adults aged 30–74 years [19]. This
algorithm incorporates age, concentrations of total chol-
esterol and high-density lipoprotein cholesterol, systolic
blood pressure, hypertension treatment status, smoking,
and diabetes. In this algorithm, diabetes is defined on
the basis of glucose measurements. For the purposes
of calculating cardiovascular risk, diabetes was defined
as having a concentration of fasting plasma glucose
≥7.0 mmol/L or the self-reported use of insulin or oral
hypoglycemic medications. Because fasting plasma glu-
cose was measured only for a subsample of participants
who attended the morning examination, analyses of pre-
dicted 10-year cardiovascular risk were limited to fasting
participants who attended the morning examination.
In addition, we included the following sociodemo-
graphic covariates: age, gender, self-reported race or eth-
nicity (white, African American, Mexican American, and
other), and educational level (less than 12 years, high
school graduate or equivalent, education beyond high
school) . We also included self-reported congestive heart
failure (Has a doctor or other health professional ever
told you that you had congestive heart failure?).
Most of the analyses were limited to participants aged
20–79 years who had a spirometric examination in the
mobile examination center. Age-adjustment with three
age groups (20–39 years, 40–59 years, and 60–79 years)
was performed by using the direct method and the pro-
jected year 2000 U.S. population. Differences in means
and proportions were tested with t-tests. Prevalence
ratios that were generated from log-binomial regression
analyses were used to examine associations between
cardiovascular risk factors and respiratory impairment
independent of sociodemographic factors and other car-
diovascular risk factors. We used SAS and SUDAAN,
the latter to account for the complex sampling design of
the surveys. Sample sizes shown in the text and tables
are unweighted numbers. Sampling weights were used to
produce estimates (means, percentages, and prevalence
ratios) that are representative of the civilian noninstitu-
tionalized population in the United States.
Results
Of the 10981 participants aged 20–79 years who had an
examination in NHANES 2007–2010, 9172 had a spiro-
metric examination, and 9047 had values for FEV1 and
FVC. Excluding participants who lacked a value for
height reduced the number of participants to 9024.
Limiting participants to those who had a complete
examination and met or exceeded American Thoracic
Society data collection standards left 7890 participants.
After additional exclusions for participants with missing
data for other study variables, 7249 participants were
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included in the analysis based on prebronchodilator test-
ing and 6816 based on postbronchodilator testing.
Among the 7249 participants, 80.9% had a normal pul-
monary function test, 5.7% had a restrictive impairment,
7.9% had a mild obstructive impairment, and 5.5% had a
moderate or severe obstructive impairment. Participants
with a normal pulmonary function test, restrictive im-
pairment, and obstructive impairment differed in mean
age, gender distribution, race or ethnic distribution, and
educational distribution (Table 1).
After age-adjustment, respiratory function status was
significantly associated with all cardiovascular risk fac-
tors except low-density lipoprotein cholesterol (Table 1,
Figure 1). However, the pattern of risk differed between
adults with a restrictive impairment and an obstructive
impairment. Compared to adults with normal pulmon-
ary function, those with a restrictive impairment were
more likely to have an elevated concentration of coti-
nine, hypertension, low levels of high-density lipoprotein
cholesterol, an increased concentration of C-reactive
protein >3 mg/l, an increased prevalence of diabetes,
obesity, and abdominal obesity, an increased level of
physical activity, and an elevated 10-year cardiovascular
risk of >20%. Compared to adults with normal pulmon-
ary function, those with a mild obstructive impairment
were more likely to be a current smoker, have an ele-
vated concentration of cotinine, have a decreased con-
centration of C-reactive protein, have a lower prevalence
of diabetes, obesity, and abdominal obesity, and have an
elevated 10-year cardiovascular risk of >20%. Compared
to adults with normal pulmonary function, those with a
moderate or severe obstructive impairment were more
likely to be a current smoker and have an elevated con-
centration of cotinine, whereas they were less likely to
have an elevated concentration of total cholesterol and
non-high-density lipoprotein cholesterol. However, per-
sons with moderate or severe obstructive impairment
had a higher age-adjusted percentage with an overall 10-
year cardiovascular risk >20% than persons with normal
pulmonary function (16.7% vs. 8.1%, p <0.001).
The results from multivariate analyses using pre-
bronchodilator data are shown in Table 2. Compared to
participants with a normal pulmonary function test,
those with a restrictive impairment were more likely to
be a current smoker, to have an elevated concentration
of cotinine, to have low levels of high-density lipoprotein
cholesterol, to have an elevated concentration of C-
reactive protein >3 mg/l, and to have an elevated preva-
lence of diagnosed diabetes and obesity. Compared to
adults with normal pulmonary function, those with a
mild obstructive impairment were more likely to be a
current smoker, have an elevated concentration of coti-
nine, and have a lower prevalence of diabetes, obesity,
and abdominal obesity. Compared to adults with normal
pulmonary function, those with at least moderate ob-
structive impairment were more likely to be a current
smoker and have an elevated concentration of cotinine,
were less likely to have an elevated concentration of total
cholesterol and non-high-density lipoprotein cholesterol,
and were more likely to have an elevated concentration
of C-reactive protein.
Because age is an important component of the calcula-
tion of predicted 10-year cardiovascular risk and because
differences in age among the four groups of respiratory
status were present, we calculated 10-year cardiovascular
risk for participants 50–74 years and again for those
aged 55–74 years (Table 3). For the former group, sig-
nificantly larger percentages of adults with a restrictive
impairment or obstructive impairment had a risk >20%
than adults without an impairment of lung function. In
the 55–74 year-old age group, only adults with a moder-
ate or worse obstructive impairment were significantly
more likely to have an elevated risk for cardiovascular
disease, although participants with a restrictive impair-
ment had a borderline significant increased risk for car-
diovascular disease (p = 0.061).
Postbronchodilator results
We repeated the results shown in Tables 1, 2, and 3
using the postbronchodilator data. Additional tables
corresponding to Tables 1, 2, and 3 are included in
Additional file 1.
Discussion
Our results show that, compared to adults who have a
normal pulmonary function, adults who have impaired
lung function, whether restrictive or obstructive in na-
ture, have a number of abnormalities in their cardiovas-
cular risk profile that might help to explain their
increased risk for cardiovascular mortality. However, the
comparisons of cardiovascular risk profiles with persons
who had normal pulmonary function differed somewhat
between adults with a restrictive impairment and those
with an obstructive impairment. Persons with restrictive
impairment showed more abnormalities of cardiometa-
bolic factors compared to the normal group whereas
the latter had primarily higher rates of smoking
along with evidence of systemic inflammation compared
to the normal group. Furthermore, the predicted 10-year
cardiovascular risk was increased among adults aged
50–74 years with either a restrictive or obstructive
impairment.
Relatively few studies, especially population-based
studies in the United States, have compared the cardio-
vascular risk factor profile in people with COPD to that
in people without COPD. In a cohort of 91932 members
of the Kaiser Permanente Medical Care Program of
Northern California, patients with COPD identified from
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Table 1 Age-adjusted means and percentages (standard error) of sociodemographic and cardiovascular factors among
7249 U.S. adults aged 20–79 years, by categories of respiratory impairment based on prebronchodilator data, National
Health and Nutrition Examination Survey 2007-2010
Respiratory impairment
Obstructive impairment
None
(N=5792)
Restrictive
(N=478)
Mild
(N=551)
Moderate/severe/
very severe (N=428)
P
restrictive‡
P
mild OI‡
P moderate/
severe OI‡
Age (years) 42.5 (0.3) 50.1 (0.9) 54.9 (0.7) 55.2 (0.7) <0.001 <0.001 <0.001
Men (%) 46.5 (0.7) 56.4 (3.1) 66.0 (3.0) 58.4 (3.6) 0.002 <0.001 0.004
Race or ethnicity (%)
White 70.4 (2.3) 54.7 (5.1) 84.1 (2.8) 78.0 (4.4) 0.001 <0.001 0.042
African American 9.9 (1.0) 9.3 (1.4) 7.9 (1.9) 7.7 (1.6)
Mexican American 9.3 (1.4) 8.8 (1.9) 3.4 (1.1) 1.2 (0.4)
Other 10.4 (1.1) 27.2 (4.0) 4.5 (1.3) 13.1 (3.6)
Education (%)
<High school 16.4 (0.9) 19.7 (2.0) 17.2 (2.5) 22.5 (3.4)
High school graduate or equivalent 22.2 (0.9) 25.0 (3.8) 28.4 (3.5) 34.4 (3.8)
>High school (%) 61.4 (1.4) 55.3 (4.1) 54.4 (4.0) 43.1 (4.9) 0.112 0.063 <0.001
Smoking status (%)
Current 18.8 (0.7) 24.2 (3.2) 35.7 (2.4) 48.6 (3.8) 0.081 <0.001 <0.001
Former 23.0 (0.9) 23.2 (2.8) 26.6 (3.0) 26.4 (3.7)
Never 58.2 (1.2) 52.6 (4.3) 37.8 (3.6) 25.0 (3.4)
Cotinine >10 ng/ml (%) 22.9 (0.8) 29.3 (3.5) 44.5 (3.5) 53.1 (4.3) 0.048 <0.001 <0.001
Hypertension (%) 25.1 (0.8) 34.1 (2.9) 25.8 (2.4) 30.8 (3.5) 0.003 0.761 0.101
Total cholesterol ≥5.17 mmol/L (%) 45.2 (0.9) 41.4 (2.6) 43.4 (3.6) 36.8 (3.4) 0.212 0.619 0.027
High-density lipoprotein cholesterol
<1.03 mmol/L in men, <1.29 mmol/L
in women (%)
32.1 (1.1) 50.2 (2.9) 26.7 (3.2) 36.4 (5.1) <0.001 0.085 0.397
Non-high-density lipoprotein
cholesterol ≥130 mg/dl (%)
62.0 (0.8) 61.8 (2.9) 62.2 (3.6) 53.9 (3.9) 0.946 0.951 0.048
Low-density lipoprotein
cholesterol ≥2.59 mmol/L* (%)
67.7 (0.9) 69.0 (4.0) 72.4 (4.9) 61.1 (6.0) 0.747 0.350 0.290
C-reactive protein >3 mg/l (%) 30.1 (0.7) 48.8 (3.1) 22.9 (2.5) 34.1 (4.6) <0.001 0.010 0.371
FPG ≥7.0 mmol/L or diagnosed
diabetes† (%)
9.1 (0.7) 25.8 (3.7) 3.2 (0.7) 10.0 (1.8) <0.001 <0.001 0.678
Diagnosed diabetes (%) 6.1 (0.5) 18.6 (2.3) 3.9 (0.6) 7.3 (1.3) <0.001 0.002 0.414
Body mass index ≥30 kg/m2 (%) 35.4 (1.0) 51.4 (2.9) 21.6 (2.7) 30.0 (4.0) <0.001 <0.001 0.206
Abdominal obesity (%) 53.7 (1.1) 65.1 (2.9) 35.8 (2.9) 50.2 (4.0) <0.001 <0.001 0.434
Leisure-time physical activity
<150 min/week (%)
59.9 (1.5) 69.9 (2.8) 55.3 (3.0) 65.3 (4.3) 0.004 0.210 0.225
Congestive heart failure (%) 0.8 (0.1) 3.2 (0.8) 0.9 (0.2) —§ 0.003 0.550 0.069
10-Year cardiovascular risk†
<10% 77.3 (0.9) 68.9 (3.9) 73.2 (2.3) 68.9 (2.7)
10-20% 14.6 (1.0) 16.4 (2.8) 15.4 (2.2) 14.4 (2.6)
>20% 8.1 (0.5) 14.7 (2.3) 11.4 (1.2) 16.7 (2.0) 0.004 0.012 <0.001
OI obstructive impairment.
*Fasting subsample. Sample sizes are 2537, 220, 270, and 180, respectively.
†Fasting subsample. Sample sizes are 2581, 227, 272, and 183, respectively.
‡P-values are for comparison with participants with no respiratory impairment.
§Relative standard error >30%.
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Figure 1 Age-adjusted percentages (standard error) of selected cardiovascular factors among 7249 U.S. adults aged 20-79 years, by
categories of respiratory impairment based on prebronchodilator data, National Health and Nutrition Examination Survey 2007-2010.
OI = obstructive impairment.
Table 2 Adjusted* prevalence ratios (95% confidence interval) for cardiovascular risk factors among 7249 U.S. adults
aged 20–79 years, by categories of respiratory impairment based on prebronchodilator data, National Health and
Nutrition Examination Survey 2007-2010
Respiratory impairment
Obstructive impairment
None Restrictive Mild Moderate/severe/ very severe P†
Current smoking 1.00 1.23 (1.01, 1.51) 1.68 (1.40, 2.00) 2.26 (1.90, 2.70) <0.001
Cotinine >10 ng/ml 1.00 1.23 (1.04, 1.46) 1.62 (1.37, 1.90) 2.00 (1.69, 2.36) <0.001
Hypertension 1.00 0.99 (0.86, 1.15) 1.00 (0.88, 1.15) 1.03 (0.88, 1.21) 0.974
Total cholesterol ≥5.17 mmol/L 1.00 0.91 (0.78, 1.06) 0.90 (0.80, 1.02) 0.85 (0.73, 0.99) 0.068
High-density lipoprotein cholesterol
<40 mg in men, <1.29 mmol/L in women
1.00 1.18 (1.04, 1.34) 0.95 (0.78, 1.16) 1.04 (0.85, 1.26) 0.188
Non-high-density lipoprotein cholesterol ≥130 mg/dl 1.00 0.92 (0.83, 1.01) 0.93 (0.84, 1.02) 0.86 (0.78, 0.95) 0.017
Low-density lipoprotein cholesterol ≥2.59 mmol/L‡ 1.00 0.95 (0.84, 1.08) 1.00 (0.89, 1.13) 0.91 (0.80, 1.04) 0.514
C-reactive protein >3 mg/l 1.00 1.21 (1.05, 1.40) 1.02 (0.89, 1.18) 1.17 (1.03, 1.33) 0.014
Diagnosed diabetes 1.00 1.84 (1.40, 2.41) 0.70 (0.50, 0.99) 1.01 (0.68, 1.51) <0.001
Diagnosed diabetes of fasting plasma glucose
≥7.0 mmol/L§
1.00 1.65 (1.19, 2.30) 0.45 (0.30, 0.68) 0.83 (0.54, 1.27) <0.001
Body mass index ≥30 kg/m2 1.00 1.16 (1.03, 1.30) 0.60 (0.50, 0.72) 0.83 (0.68, 1.01) <0.001
Abdominal obesity 1.00 1.07 (0.99, 1.16) 0.75 (0.69, 0.83) 0.96 (0.86, 1.07) <0.001
Leisure-time physical activity <150 min/week 1.00 1.05 (0.97, 1.14) 0.99 (0.89, 1.10) 1.05 (0.97, 1.13) 0.479
*Adjusted for age, gender, race or ethnicity, educational status, smoking status (except for cotinine concentration), cotinine concentration (except smoking status),
systolic blood pressure (except hypertension), high-density lipoprotein cholesterol concentration (except non-high-density lipoprotein cholesterol concentration),
non-high-density lipoprotein cholesterol concentration (except high-density lipoprotein cholesterol), C-reactive protein concentration, diagnosed diabetes, body
mass index (except waist circumference), waist circumference (except body mass index), leisure-time physical activity, and history of congestive heart failure.
Hypercholesterolemia was adjusted for all above factors except non-high-density lipoprotein cholesterol. Low-density lipoprotein cholesterol was adjusted for all
factors except non-high-density lipoprotein cholesterol.
†P-value for Satterthwaite adjusted F-test.
‡Sample size is 3207.
§Sample size is 3263.
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administrative databases were more likely to have dia-
betes, hypertension, and hyperlipidemia and to be obese
than patients without COPD [6]. In the Copenhagen
City Heart Study, the GOLD classification system was
used to establish the respiratory status of participants
[20]. The unadjusted percentages of elevated concentra-
tions of HbA1c and C-reactive protein as well as the
mean concentration of total cholesterol, mean systolic
blood pressure, mean body mass index, and current
smoking were higher in 1036 participants with COPD
than in 4854 without COPD. However, many of the dif-
ferences were likely attributable to the much higher
mean age in participants with COPD. An analysis of
patients with COPD from the United Kingdom identified
from the General Practice Research Database reported
that patients with COPD were more likely to be under-
weight, less likely to be obese, and less likely to have
hypertension than patients without COPD [10]. In an-
other study that used spirometric testing to establish the
COPD status, hypertensive patients with COPD
(N=1622) were more likely to smoke and have a higher
mean systolic blood pressure than hypertensive patients
without COPD (N=1184), but the prevalence of diabetes
in the two groups did not differ significantly [9]. In a Ko-
rean study of 4001 participants aged ≥18 years, those
with obstructive lung function had a higher unadjusted
mean waist circumference, systolic blood pressure,
diastolic blood pressure, and higher concentrations of
glucose and triglycerides but lower concentration of
high-density lipoprotein cholesterol [21]. Thus, the avail-
able data do not paint a consistent picture about risk
factors for cardiovascular disease among people with
COPD. Some of the inconsistency may be attributable to
differences in methods used to identify participants with
COPD (identification from administrative data bases,
use of pulmonary function test to categorize COPD sta-
tus), sample size of the studies, definition of risk factors
(self-reported data, administrative data bases, measured
data), or other characteristics of study populations. Our
results confirm that advanced age and a high prevalence
of smoking are the two factors that contribute substan-
tially to the risk for cardiovascular disease among U.S.
adults with COPD.
Little information about predicted cardiovascular risk
in function of pulmonary function status is available. In
an Italian study of 12933 participants aged ≥35 years,
the CUORE risk score was not significantly associated
with the ratio of FEV1/FVC [22].
People with an obstructive impairment continued to
smoke at high rates. Consequently, smoking cessation
efforts are critical to reducing the risk for cardiovascular
disease among these people. A large body of research
has examined the effectiveness of numerous approaches
to smoking cessation such as clinical interventions (in-
cluding behavioral approaches and medications), system
interventions, and quitlines [23]. Despite this large body
of research concerning the best approaches to initiate
and sustain smoking cessation, the report “Treating
Tobacco Use and Dependence: 2008 Update” acknowl-
edged the need for additional research concerning the
effectiveness of counseling among people with COPD. In
view of the strong link between smoking and COPD and
Table 3 Adjusted prevalence ratios (95% confidence interval) for 10-year cardiovascular risk >20% among U.S. adults,
by categories of respiratory impairment based on prebronchodilator data, National Health and Nutrition Examination
Survey 2007-2009
Respiratory impairment
Obstructive impairment (OI)
None Restrictive Mild Moderate/severe/very severe
Age 50–74 years
No. risk >20% / no. at risk* 224 / 902 53 / 123 61 / 169 53 / 117
Median age (years) 57 60 60 60
Unadjusted prevalence (standard error) (%) 16.5 (1.2) 34.4 (5.6) 24.3 (4.1) 38.5 (4.5)
Unadjusted prevalence ratio 1.00 2.08 (1.54, 2.80) 1.47 (1.04, 2.09) 2.33 (1.72, 3.15)
Adjusted prevalence ratio† 1.00 1.64 (1.16, 2.31) 1.56 (1.13, 2.15) 2.19 (1.62, 2.97)
Age 55–74 years
No. risk >20% / no. at risk* 199 / 640 49 / 99 56 / 143 46 / 95
Median age (years) 61 62 61 63
Unadjusted prevalence (standard error) (%) 23.1 (1.7) 41.5 (6.7) 26.7 (4.8) 43.8 (5.4)
Unadjusted prevalence ratio 1.00 1.79 (1.34, 2.41) 1.16 (0.82, 1.63) 1.90 (1.36, 2.63)
Adjusted prevalence ratio† 1.00 1.40 (0.98, 1.99) 1.22 (0.90, 1.64) 1.84 (1.36, 2.50)
*Unweighted numbers.
†Adjusted for race or ethnicity, education, body mass index, C-reactive protein, and leisure-time physical activity.
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the high rates of smoking among people with COPD,
such research is urgently needed. A meta-analysis of ran-
domized controlled trials found that the combination of
smoking cessation counseling plus the use of nicotine
replacement therapy yielded the best rate of smoking
cessation, followed by the combination of smoking ces-
sation counseling plus the use of antidepressant medica-
tions, and smoking cessation counseling alone [24].
Among patients with COPD, both intensive counseling
and pharmacotherapy yielded superior cost-effectiveness
compared to minimal counseling [25].
Previous studies have shown that COPD is associated
with increased concentrations of C-reactive protein [26-
28]. Our analysis found that concentrations of C-reactive
protein were elevated in adults with moderate or severe
COPD but not in those with a mild obstructive impair-
ment. Because C-reactive protein is considered to be a
risk factor for cardiovascular disease [29], the presence
of a systemic inflammatory component as evidenced by
elevated concentrations of C-reactive protein in people
with COPD may help to explain the increased risk for
cardiovascular disease in this population.
In addition to excess levels of smoking and elevated
concentrations of C-reactive protein, several additional
physiological disruptions may contribute to the
increased risk for cardiovascular disease in people with
COPD including increased circulating platelet-monocyte
aggregates [30], impaired coronary blood flow [31],
endothelial dysfunction [32,33], coagulation abnormal-
ities [32], oxidative stress [34], and increased arterial
stiffness [35].
The impact of medications used to treat COPD pro-
vides another possible explanation for the increased risk
for cardiovascular disease [36]. Evidence has been pre-
sented that the use of short-acting anticholinergic agents
may increase mortality from cardiovascular disease [37].
The data concerning the effect of long-acting anticholin-
ergic agents on adverse cardiovascular events has gener-
ated intense discussion [38-43]. Furthermore, a meta-
analysis of randomized controlled trials concluded that
the use of beta-2-agonists increased cardiovascular
events [44]. Studies concerning the possible effect of
inhaled corticosteroids on cardiovascular outcomes have
yielded conflicting data with observational studies show-
ing a possible benefit from the use of these agents and
data from randomized controlled trials showing no
such effect [45]. Because patients with COPD are sus-
ceptible to acute exacerbations of their disease in part
from respiratory infections, some classes of antibiotics
used to treat these infections such as macrolides and
quinolones could conceivably result in adverse cardio-
vascular events [46].
Our results suggest that people with a mild obstructive
impairment do not have a particularly adverse set of
cardiometabolic risk factors compared to people
with normal respiratory function. Thus, the clinical ap-
proach to cardiovascular risk reduction in this popula-
tion should be similar as that for the general population
[47-52]. Although research concerning management of
cardiovascular risk factors specifically in patients with
COPD is limited, some data suggest that the use of beta-
blockers in patients may reduce cardiovascular morbid-
ity and mortality. In a study of 1205 patients with COPD
undergoing vascular surgery, beta-blocker therapy, par-
ticularly high-dose therapy, was associated with reduced
mortality [53]. In addition, the use of angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers have also been shown to reduce cardiovascular
events in cohorts of patients with COPD [54]. Interest-
ingly, some treatments for COPD may provide cardio-
vascular benefits to patients with COPD. For example,
pulmonary rehabilitation in patients with COPD was
associated with improvements in aortic pulse wave vel-
ocity, blood pressure, and concentration of total choles-
terol [55].
Our analyses of the prebronchodilator data indicated
that the prevalence of hypercholesterolemia was some-
what lower among participants with at least moderate
obstructive impairment. The explanation for this finding
is unclear, and it could represent a spurious finding. The
age-adjusted self-reported use of cholesterol-lowering
medications and mean intakes of saturated fat and poly-
unsaturated fat were similar for participants with normal
lung function and those with at least moderate obstruct-
ive impairment (data not shown). Results from other
studies yield mixed evidence about a reduced prevalence
of hypercholesterolemia among adults with COPD. In a
large study from Canada, 7.9% of patients with COPD
and 10.9% of patients without COPD had hypercholes-
terolemia, a difference which was significantly different
[7]. Mean concentrations of low-density lipoprotein
cholesterol were also lower in a population of patients
with COPD evaluated for lung transplantation [56]. In
contrast in a Danish study, unadjusted mean concentra-
tions of total cholesterol were positively associated with
severity of COPD [20]. In an Italian study, unadjusted
mean concentrations of total cholesterol and low-density
lipoprotein cholesterol did not differ between partici-
pants with and without COPD [9]. Also, unadjusted
mean concentrations of total cholesterol and low-density
lipoprotein cholesterol did not differ significantly be-
tween patients with emphysema and those without this
condition in another study [57].
In recent years, the potential role of treatment
with statins in reducing morbidity and mortality
among people with COPD has drawn substantial interest
[58-60]. The use of statins to manage hypercholesterol-
emia should yield similar benefits in people with COPD
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as in those without this condition. Because statins have
been shown to have pleiotropic actions including anti-
inflammatory and antioxidant effects [61] and because
COPD has a powerful inflammatory component [62],
statins could conceivably modulate the inflammation
unleashed by COPD. Whether statins will reduce cardio-
vascular morbidity and mortality in people with COPD
to the same extent as in people without COPD or
whether there is an added benefit to the use of statins in
people with COPD remains a question to be addressed
by future randomized controlled trials. Of note is that a
recent study showed that the use of statins was asso-
ciated with interstitial lung disease among smokers [63].
A heterogeneous set of disorders can produce a re-
strictive pattern on spirometry [64]. These disorders can
be broadly grouped into three categories: decreased lung
compliance (interstitial lung disease, pneumonia, sar-
coidosis, acute respiratory distress syndrome), decreased
muscle strength (neuromuscular disease, dysfunction of
diaphragm, injury of the phrenic nerve), and extrapul-
monary disease (pleural effusion, pleural thickening,
obesity, metabolic syndrome, kyphoscoliosis). In turn,
some of these conditions such as interstitial lung disease
have a lengthy list of etiologies.
Observational studies have shown that people with a
restrictive impairment have an increased mortality rate
from all-causes as well as diseases of the circulatory sys-
tem [65]. Yet, the cardiovascular risk profile of people
with restrictive impairment has not been well character-
ized. In an analysis of 4320 U.S. adults aged 25–74, par-
ticipants with a restrictive impairment were more likely
to be current smokers, be obese, have hypertension, and
have diabetes than participants without restriction [65].
A study of 121,965 French participants showed that a re-
strictive ventilator pattern was associated with several
factors (lipids, glucose-blood pressure, and abdominal
obesity) derived from a factor analysis of cardiometa-
bolic variables [66]. Furthermore, adults with a restrict-
ive impairment also show evidence of inflammation [27].
In our analysis, the presence of a number of cardiometa-
bolic abnormalities (increased body mass index, low
high-density lipoprotein cholesterol, increased diabetes,
elevated C-reactive protein) among the adults with a
restrictive impairment is broadly consistent with the
aforementioned studies and suggests that these adults
are at increased risk for cardiovascular disease. Although
our analyses did not specifically examine the association
between metabolic syndrome and restrictive ventilatory
pattern, the significant associations between several of
the cardiovascular risk factors and restrictive impair-
ment is consistent with previous studies that have
reported associations between metabolic syndrome and
restrictive impairment [21,66-69]. The general profile of
these adults suggests that, as a group, they might benefit
from weight management, improved nutrition, and
increased physical activity in addition to smoking
cessation. Furthermore, pharmacotherapy to address
hyperglycemia or raise concentrations of high-density
lipoprotein cholesterol may help to lessen the cardiovas-
cular risk in these adults.
The major strength of this study is the large nationally
representative study population of U.S. adults with spir-
ometry and cardiovascular measurements. The principal
limitation of our study was the very small number of
adults with a very severe obstructive impairment. There-
fore, we were unable to generate results for this specific
group. Even the number of adults with severe obstruct-
ive impairment proved to be limited leading us to group
moderate, severe, and very severe obstructive impair-
ment together.
Although the results based on postbronchodilator data
in large measure were similar to the results based on
prebronchodilator data, these postbronchodilator results
should be cautiously interpreted given the substantial
attrition of attendance with 25% of participants aged
20–79 years excluded for safety reasons and another
21% of participants not having the postbronchodilator
examination. The safety exclusions included a number
of reasons that excluded a number of participants at
increased risk for cardiovascular disease: uncontrolled
blood pressure, irregular pulse on examination, taking
medication for major arrhythmia, implanted defibrillator,
and current treatment for cardiac disease.
Addressing the cardiovascular risk factors among per-
sons with restrictive or obstructive pulmonary function
would provide support to the federal interagency Million
Hearts Initiative to prevent 1 million heart attacks and
strokes over the next 5 years [70,71]. The proposed ef-
fective clinical services that could reduce cardiovascular
disease risk, morbidity, and mortality in this patient
population include aspirin therapy, blood pressure
control, cholesterol management, and smoking cessation
[71]. This initiative has been expanded to include
community-level policies and programs designed to re-
duce exposure to tobacco use, policies to reduce sodium
content of food, and policies to eliminate artificial trans
fatty acids from the diet [70].
Conclusion
The high prevalence of smoking among adults with an
obstructive impairment was the principal abnormal car-
diovascular risk factor, whereas a broader set of cardio-
metabolic abnormalities among adults with a restrictive
impairment contributes to the risk for cardiovascular
disease. Although both groups with impaired lung func-
tioning would benefit from smoking cessation, many
adults with a restrictive impairment require management
of other cardiometabolic factors as well. By providing
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insights about the status of cardiovascular risk factors
that may be partially responsible for the excess morbid-
ity and mortality from cardiovascular disease among
adults with obstructive and restrictive lung disease, our
results may help to increase the understanding of how
best to manage cardiovascular risk in these adults.
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